



## Jay Michael S. Balagtas

Clinical Professor, Pediatrics - Hematology & Oncology

### CLINICAL OFFICE (PRIMARY)

- **Oncology**

750 Welch RD STE 200

Palo Alto, CA 94304

Tel (650) 723-5535      Fax (650) 723-5231

### Bio

---

#### CLINICAL FOCUS

- Ped Hematology/Oncology
- Pediatric Hematology-Oncology

#### ACADEMIC APPOINTMENTS

- Clinical Professor, Pediatrics - Hematology & Oncology

#### PROFESSIONAL EDUCATION

- Medical Education: New York Medical College (1998) NY
- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2009) CA
- Residency: United States Naval Medical Center San Diego Pediatric Residency (2003) CA
- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2011)

### Research & Scholarship

---

#### CLINICAL TRIALS

- A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma, Recruiting
- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours, Recruiting
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma, Recruiting
- Phase I GD2 CAR T Cells for H3K27M-mutant Diffuse Midline Glioma (DMG), Recruiting
- Phase I/II Selinexor & RT in Newly-Dx Pediatric Diffuse Intrinsic Pontine Glioma & High-Grade Glioma, Recruiting
- Phase II Blinatumomab in Combo w/ Nivolumab (Checkpoint Inhibitor of PD-1) in B-ALL w/ First Relapse, Recruiting
- Phase II Chemotherapy + Response-Based WVSCI in Localized Non-Germinomatous CNS Germ Cell Tumor, Recruiting
- Phase II Inotuzumab Ozogamicin in Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia(B-ALL), Recruiting
- Phase II Intravitreal Melphalan for Intraocular Retinoblastoma, Recruiting

- Phase II/III VEGFR2/MET Inhibitor Cabozantinib +/- Cytotoxic Chemo in Newly Diagnosed Osteosarcoma, Recruiting
- Phase III 131I-Metaiodobenzylguanidine or Crizotinib +Intensive Tx in High-Risk Neuroblastoma, Recruiting
- Phase III Active Surveillance in Low Risk +Carboplatin vs Cisplatin in Standard Risk GermCell Tumors, Recruiting
- Phase III Carboplatin &Vincristine vs Selumetinib in LGG Not Associated w/BRAFV600E Mutations or NF1, Recruiting
- Phase III in Newly Diagnosed Very Low-Risk & Low-Risk Fusion Negative Rhabdomyosarcoma, Recruiting
- Phase III InotuzumabOzogamicin &PostInductionChemo in HighRiskB-ALL/MixdPhenotypAcuteLeukemia &B-LLy, Recruiting
- Phase III Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Osteosarcoma, Recruiting
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma, Recruiting
- ALinC 17 Treatment for Patients with Low Risk Acute Lymphoblastic Leukemia, Not Recruiting
- Biology Study of Transient Myeloproliferative Disorder in Children with Down Syndrome, Not Recruiting
- Carboplatin + Radiation & Isotretinoin for Non-average Risk of Medulloblastoma/PNET, Not Recruiting
- Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens, Not Recruiting
- Classification of Acute Lymphoblastic Leukemia, Not Recruiting
- Classification of Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- COG Study for Collecting and Banking Ewing Sarcoma Specimens, Not Recruiting
- Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens, Not Recruiting
- Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer, Not Recruiting
- Combination Chemotherapy in Newly Diagnosed T-Cell ALL or T-cell Lymphoblastic Lymphoma, Not Recruiting
- Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma, Not Recruiting
- Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia, Not Recruiting
- Effects of Chemotherapy on Spermatogenesis &Steroidogenesis in Peds & AYA Survivors of Osteosarcoma, Not Recruiting
- Intensified Tyrosine Kinase Inhibitor Therapy in Philadelphia Chromosome Positive ALL, Not Recruiting
- Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma, Not Recruiting
- Intergroup Trial in B-Cell NHL / B-AL: Eval of Rituximab Efficacy & Safety in High Risk Patients, Not Recruiting
- Key Adverse Events after Childhood Cancer , Not Recruiting
- LEAHRN (Late Effects After High-Risk Neuroblastoma), Not Recruiting
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol, Not Recruiting
- Neuroblastoma Biology Studies, Not Recruiting
- Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer, Not Recruiting
- Optimize Tx Strategies for Resectable Osteosarcoma Based on Histologic Response to Pre-Op Chemo, Not Recruiting
- Phase 2 Subprotocol Selumetinib in Tumors Harboring Activating MAPK Pathway Mutations, Not Recruiting
- Phase I Palbociclib (IND#141416) a CDK 4/6 Inhibitor In Combo w/ Chemotherapy In Relapsed ALL or LL, Not Recruiting
- Phase I/II Bosutinib in New Dx Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia, Not Recruiting
- Phase I/II Brentuximab Vedotin and Gemcitabine in Younger Patients with Relapsed/Refractory HL, Not Recruiting
- Phase I/II Nivolumab in Recurrent /Refractory Solid Tumors as Single Agent & in Combo w/ Ipilimumab, Not Recruiting
- Phase I/II Palbociclib +/-Irinotecan&Temozolomide and +/- Topotecan&Cyclophosphamide in Peds R/R ST, Not Recruiting
- Phase II Azacitidine + Chemotherapy in Infants w/ ALL and KMT2A (MLL) Gene Rearrangement, Not Recruiting
- Phase II Bevacizumab & Temozolomide in Combo with IV+Cyclophosphamide in Rhabdomyosarcoma, Not Recruiting

- Phase II Bortezomib plus Intensive Re-Induction Therapy in Relapsed ALL and Lymphoblastic Lymphoma, Not Recruiting
- Phase II ch14.18 (Dinutuximab) in Combo w/ Sargramostim (GM-CSF) in Recurrent Osteosarcoma, Not Recruiting
- Phase II Dasatinib and Chemotherapy in Pediatric Newly Diagnosed Ph+ ALL, Not Recruiting
- Phase II IGF-1R Monoclonal Antibody Ganitumab + Multiagent Chemo in Metastatic Ewing Sarcoma, Not Recruiting
- Phase II Irinotecan/Temozolomide + Temozolomide or ch14.18 in Refractory/ Relapsed/ Progressive NB, Not Recruiting
- Phase II Irinotecan/Temozolomide/Dinutuximab +/-Eflornithine in Relapsed or Refractory Neuroblastoma, Not Recruiting
- Phase II JAK1/JAK2 Inhibitor Ruxolitinib + Chemotherapy in Acute Lymphoblastic Leukemia, Not Recruiting
- Phase II MEK inhibitor Trametinib in Relapsed or Refractory Juvenile Myelomonocytic Leukemia, Not Recruiting
- Phase II Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor, Not Recruiting
- Phase II Nilotinib in Pediatric Newly Diagnosis of Ph+ CML, Not Recruiting
- Phase II Nirogacestat (PF-03084014) in Youth w/ Progressive Surgically Unresectable Desmoid Tumors, Not Recruiting
- Phase II Nivolumab + Brentuximab Vedotin in Relapsed/Refractory CD30 + Classic Hodgkin Lymphoma, Not Recruiting
- Phase II of Brentuximab Vedotin with Chemotherapy for Newly Diagnosed ALCL, Not Recruiting
- Phase II Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors, Not Recruiting
- Phase II Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients, Not Recruiting
- Phase II Response-Based Radiation Therapy in Localized CNS Germ Cell Tumors, Not Recruiting
- Phase II Stopping TKI to Assess Treatment-Free Remission in Pediatric CML - Chronic Phase (CML-CP), Not Recruiting
- Phase II Treatment of Newly Diagnosed Diffuse Anaplastic & Relapsed Favorable Histology Wilms Tumors, Not Recruiting
- Phase II Veliparib(ABT-888) &Local Irradiation +Maintenance Veliparib &Temozolomide, in Newly Dx HGG, Not Recruiting
- Phase II XL184 (Cabozantinib) in Pediatric Refractory Sarcomas, Wilms Tumor, & Other Rare Tumors, Not Recruiting
- Phase II/III Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT), Not Recruiting
- Phase II/III Vorinostat, Temozolomide or Bevacizumab + XRT then Bev+Tem in New Dx High-Grade Glioma, Not Recruiting
- Phase III of Blinatumomab in in 1st Relapse of Childhood B-Lymphoblastic Leukemia, Not Recruiting
- Phase III Blinatumomab +/- ChemoTx in NewDx Standard Risk /Down Syndrome B-ALL & Tx Localized BB-LLy, Not Recruiting
- Phase III Bortezomib on a Modified Augmented BFM Backbone in Newly Diagnosed T-ALL & T-LLy, Not Recruiting
- Phase III Chimeric Anti-GD2 in High Risk Neuroblastoma Following Myeloablative Tx and Autologous SCR, Not Recruiting
- Phase III Combination Chemotherapy +/- Temozolomide in Intermediate Risk Rhabdomyosarcoma , Not Recruiting
- Phase III Combo Chemotherapy in Newly Diagnosed High-Risk B ALL & Ph-Like TKI Sensitive Mutations, Not Recruiting
- Phase III de novo AML w/ Bortezomib & Sorafenib in High Allelic Ratio FLT3/ITD, Not Recruiting
- Phase III Imatinib in Combo w/ 2 Cytotoxic Chemotherapy Backbones in Philadelphia Chromosome+ ALL, Not Recruiting
- Phase III in Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid, Not Recruiting
- Phase III Intravenous Gammaglobulin Tx for Neuroblastoma + Opsoclonus-Myoclonus-Ataxia Syndrome, Not Recruiting
- Phase III Memantine for Neurocognitive Protection in Kids Undergoing Cranial RT in Tx of CNS Tumors, Not Recruiting
- Phase III Nivolumab in Combo w/ Chemo-Immunotherapy in Newly Dx Primary Mediastinal B-cell Lymphoma, Not Recruiting
- Phase III Post-Radiation Chemotherapy in Newly Diagnosed Ependymoma Ages 1 to 21 years, Not Recruiting
- Phase III Reduced Therapy in Children with Low and Intermediate Risk Extracranial Germ Cell Tumors, Not Recruiting
- Phase III Risk Directed Therapy for Infants with ALL, Not Recruiting
- Phase III Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome, Not Recruiting
- Phase III Selumetinib +/-Vinblastine in non-NF1 non-TSC w/ Recurrent or Progressive Low-GradeGliomas, Not Recruiting

- Phase III Selumetinib vs Carboplatin/Vincristine in Neurofibromatosis Type 1 Associated Low Grade Glioma, Not Recruiting
- Phase III Single vs Tandem Myeloablative Consolidation for High-Risk Neuroblastoma, Not Recruiting
- Phase III Utilizing Response- & Biology-Based Risk Factors to Guide Tx in Non-High-Risk Neuroblastoma, Not Recruiting
- Phase III Vincristine-Topotecan-Cyclophosphamide + Standard Chemo in Tx Non-metastatic Ewing Sarcoma, Not Recruiting
- Phase III VINO-AC + ChemoTx + VINO-CPO vs VAC + VINO-CPO in High Risk Rhabdomyosarcoma (HR-RMS), Not Recruiting
- Phase II Dabrafenib w/ Trametinib after Irradiation in Newly-Diagnosed BRAFV600-Mutant HGG, Not Recruiting
- Pilot Intravenous EZN-2285 or Intravenous Oncaspar for High-Risk Acute Lymphoblastic Leukemia, Not Recruiting
- Pilot Myeloablative Busulfan/Melphalan Consolidation After Induction Chemo in High-Risk Neuroblastoma, Not Recruiting
- Pilot of Rituximab & Third Party Latent Membrane Protein specific Cytotoxic T-Lymphocytes in SOT, Not Recruiting
- Protocol for the Enrollment on the Official COG Registry, CCRN, Not Recruiting
- Rare and Cutaneous Non-Hodgkin Lymphoma Registry, Not Recruiting
- Renal Tumors Classification, Biology, and Banking Study, Not Recruiting
- Response- and Biology-based Therapy for Intermediate-risk Neuroblastoma, Not Recruiting
- Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia using Trisenox, Not Recruiting
- Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol, Not Recruiting
- Standard Risk B-precursor Acute Lymphoblastic Leukemia, Not Recruiting
- Sub Arm C: Phase II Tazemetostat in Tumors Harboring Alterations in EZH2 or SWI/SNF Complex, Not Recruiting
- Treatment for Patients w/ Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor, Not Recruiting
- Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor, Not Recruiting
- Treatment of Children with All Stages of Hepatoblastoma, Not Recruiting
- Treatment of Down Syndrome Children with AML and MDS Under the Age of 4 Years, Not Recruiting
- Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors, Not Recruiting
- Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia, Not Recruiting
- Umbrella Long-Term Follow-Up Protocol, Not Recruiting
- Understanding the Role of Adherence in the Ethnic Differences in Survival after Childhood ALL, Not Recruiting
- VAC vs VAC Alternating w/ VI for Intermediate-Risk RMS, Not Recruiting
- Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma, Not Recruiting
- Web-based Physical Activity Intervention in Children & Adolescents w/ Acute Lymphoblastic Leukemia, Not Recruiting
- Phase II Subprotocol Palbociclib in Tumors Harboring Activating Alterations in Cell Cycle Genes, Not Specified

## Publications

---

### PUBLICATIONS

- **P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).**

Mak, B., Tran, B., Thomas, H., Walker, R., Pashankar, F., Feldman, D., Hansen, A., Huddart, R., Dunwoodie, E., Wheeler, M., Stevanovic, A., Mazhar, D., Lawrence, et al

LIPPINCOTT WILLIAMS & WILKINS.2026: TPS623

- **Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results**

Schultz, L., Aftandilian, C., Baggott, C., Corwin, N., Fujimoto, M., Li, A., Mavroukakis, S., Moon, J., Sahaf, B., Jacobs, A., Mendoza, C., Levenson, A., Frank, et al

ELSEVIER.2025: 2374

- **P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).**  
Mak, B., Tran, B., Thomas, H., Pashankar, F. D., Hansen, A., Feldman, D. R., Huddart, R. A., Wheeler, M., Dunwoodie, E., Mazhar, D., Lawrence, N., Stevanovic, A., Birtle, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS653
- **P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).**  
Mak, B., Tran, B., Pashankar, F. D., Mazhar, D., Huddart, R. A., Wheeler, M., Walpole, E., Feldman, D. R., Dunwoodie, E., Lawrence, N., Birtle, A., Wyld, D., Stevanovic, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024: TPS524
- **Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.** *Frontiers in immunology*  
Johns, C., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Dagher, R., Nadel, H., Balagtas, J., Aftandilian, C., Ramakrishna, S., Lacayo, N., Davis, K. L., Stieglitz, et al  
2024; 15: 1423487
- **A challenging case of recurrent idiopathic hemophagocytic lymphohistiocytosis (HLH) initially presenting in an infant with Pneumocystis jirovecii pneumonia**  
Solomon, B., Balagtas, J., Chien, M., Pooni, R., Balboni, I., Weinacht, K., Gernez, Y.  
SPRINGER/PLENUM PUBLISHERS.2021: S55
- **P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).**  
Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F. D., Tran, B., Jeffery, M., Mazhar, D., Huddart, R. A., Walpole, E., Stevanovic, A., Wyld, D., Hanning, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)**  
Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F., Tran, B., Jeffery, M., Mazhar, D., Huddart, R., Walpole, E., Stevanovic, A. G., Wyld, D., Hanning, et al  
WILEY.2020: 205-206
- **The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH** *JOURNAL OF THROMBOSIS AND HAEMOSTASIS*  
Tullius, B. P., Athale, U., Van Ommen, C. H., Chan, A. C., Palumbo, J. S., Balagtas, J. S., Subcomm Hemostasis & Malignan, Subcomm Pediat Neonatal Throm  
2018; 16 (1): 175–80
- **Rate of abnormal vaginal bleeding and contraception counseling in women undergoing chemotherapy** *JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY*  
Cutler, K. E., Creinin, M. D., Balagtas, J. S., Hou, M. Y.  
2016; 14 (8): 337–41
- **Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting** *PEDIATRIC BLOOD & CANCER*  
Johnston, E. E., LeBlanc, R. E., Kim, J., Chung, J., Balagtas, J., Kim, Y. H., Link, M. P.  
2015; 62 (11): 2025-2028
- **Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.** *PLoS genetics*  
Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J., Sweeney, R. T., Lai, E., Del Vecchio, C. A., Forster, A. D., Clarke, N., Montgomery, K. D., Zhu, et al  
2013; 9 (4)
- **Therapeutic Complications in a Patient With High-Risk Acute Lymphoblastic Leukemia and Undiagnosed Hereditary Hemochromatosis** *PEDIATRIC BLOOD & CANCER*  
Balagtas, J. M., Dahl, G. V.  
2012; 58 (1): 101-103

- **Liposomal amphotericin B associated with severe hyperphosphatemia** *PEDIATRIC INFECTIOUS DISEASE JOURNAL*  
Sutherland, S. M., Hong, D. K., Balagtas, J., Gutierrez, K., Dvorak, C. C., Sarwal, M.  
2008; 27 (1): 77-79